Becker's Healthcare January 22, 2025
Alexandra Murphy

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

The approval follows a priority review and is based on a clinical trial showing the drug alone led to significant improvement in depressive symptoms compared to placebo, with effects observable as early as 24 hours after being taken, according to a Jan. 21 news release from the drugmaker.

The trial demonstrated that Spravato outperformed the placebo on the Montgomery-Asberg...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Denali’s Data in Rare Enzyme Deficiency Keep It on Pace to Seek Speedy FDA Approval
“Precision Med Has Evolved as Badly As I Expected” And Other Takeaways From Former FDA Commissioner At PMWC
FDA approves clinical trials for pig organ transplants
Insurer Denies Access To Drugs Granted Accelerated Approval By FDA
FDA Approves Third Tocilizumab Biosimilar

Share This Article